Ophthalmology – Orbital Rhabdomyosarcoma

Basics

Description

Orbital rhabdomyosarcoma (RMS) is a highly malignant mesenchymal tumor showing skeletal muscle differentiation.

It is the:

Most common primary malignant orbital tumor of childhood

Orbital RMS can arise from primitive mesenchymal cells even in tissues without mature skeletal muscle.

It may involve:

• Orbit
• Eyelid
• Conjunctiva
• Extraocular muscles
• Adjacent paranasal structures

Epidemiology

Rhabdomyosarcoma is predominantly a pediatric malignancy.

Typical features include:

• Most cases occur in children
• Mean age for orbital disease is approximately the first decade of life
• Slight male predominance
• Orbital tumors constitute a minority of all pediatric RMS cases

Orbital RMS usually presents earlier than many other RMS sites because even a small orbital mass produces visible signs.

Important Clinical Principle

In a child with:

Rapidly progressive unilateral proptosis over days to weeks

orbital rhabdomyosarcoma must be considered urgently.

It can initially resemble:

• Orbital cellulitis
• Idiopathic orbital inflammation
• Hemorrhage
• Benign orbital mass

Risk Factors

Most cases are:

Sporadic

Established syndromic associations include:

• Li-Fraumeni syndrome
• Neurofibromatosis type 1
• Costello syndrome
• Noonan-spectrum/RASopathy syndromes
• Beckwith-Wiedemann spectrum in selected patients

Older reports linked parental recreational drug exposure with RMS risk, but these associations are not sufficiently established to be used clinically as major causal risk factors.

Genetics and Molecular Biology

Molecular classification has become increasingly important.

Embryonal RMS

Usually lacks FOXO1 fusion.

May show alterations involving:

• RAS pathway
• TP53
• Other developmental signaling pathways

Alveolar RMS

Classically associated with:

• PAX3-FOXO1
• PAX7-FOXO1

gene fusions.

FOXO1 fusion-positive RMS generally has a less favorable prognosis than fusion-negative disease.

Modern risk stratification increasingly relies more on:

Fusion status

than on morphology alone.

Pathology

RMS is traditionally part of the:

Small round blue cell tumor

group.

Tumor cells may show skeletal muscle differentiation with:

• Eosinophilic cytoplasm
• Rhabdomyoblasts
• Cross-striations in more differentiated cells

Immunohistochemistry commonly demonstrates:

• Desmin
• Myogenin
• MyoD1

Histologic Types

Modern categories include:

• Embryonal RMS
• Alveolar RMS
• Spindle cell/sclerosing RMS
• Pleomorphic RMS, primarily an adult tumor

Embryonal RMS

This is the most common histologic type in orbital disease.

It generally carries a more favorable prognosis than classic fusion-positive alveolar RMS.

Botryoid Pattern

Botryoid RMS is not considered a completely separate major histologic category.

It represents a characteristic grape-like growth pattern of embryonal RMS arising beneath epithelial surfaces.

In the orbit, an anterior lesion may occasionally appear as:

• Polypoid
• Grape-like
• Subconjunctival mass

Alveolar RMS

Alveolar RMS may have:

• More aggressive biologic behavior
• Greater metastatic potential

especially when FOXO1 fusion-positive.

Pathophysiology

Tumor growth causes:

• Local tissue infiltration
• Orbital mass effect
• Globe displacement
• Proptosis
• Compression of ocular structures

Advanced disease may extend into:

• Paranasal sinuses
• Intracranial structures
• Adjacent facial tissues

Clinical Presentation

Typical onset is:

Rapid over several days to weeks

Common symptoms and signs include:

• Proptosis
• Eyelid swelling
• Orbital mass
• Chemosis
• Globe displacement
• Strabismus
• Diplopia

Pain may occur but is not always present.

Proptosis

The classic presentation is:

Rapidly progressive unilateral painless proptosis

However, inflammatory features may make the lesion appear painful or infectious.

Globe Displacement

Globe displacement depends on tumor location.

A superonasal lesion may displace the globe:

• Inferiorly
• Temporally

The direction of displacement helps localize the orbital mass.

Eyelid and Conjunctival Findings

Possible findings include:

• Eyelid edema
• Ptosis
• Conjunctival injection
• Chemosis
• Visible conjunctival mass

Anterior tumors may be directly visible.

Vision

Visual acuity may initially remain relatively preserved.

Reduced vision suggests:

• Optic nerve compression
• Corneal exposure
• Severe proptosis
• Macular or retinal involvement
• Advanced orbital disease

Ocular Motility

Patients may develop:

• Restricted motility
• Diplopia
• Strabismus

because of:

• Direct muscle involvement
• Mass effect
• Mechanical displacement

Fundus Examination

Possible findings include:

• Choroidal folds
• Optic disc edema
• Venous congestion
• Optic atrophy in advanced disease

History

Ask about:

• Duration and rate of progression
• Pain
• Fever
• Recent infection
• Trauma
• Visual decline
• Diplopia
• Prior malignancy
• Family history of cancer predisposition syndromes

A history of trauma can be misleading and should not delay evaluation of a rapidly growing orbital mass.

Examination

Perform:

• Visual acuity
• Pupils
• Color vision
• Proptosis measurement
• Eyelid examination
• Ocular motility
• Globe displacement assessment
• Slit-lamp examination
• Dilated fundus examination
• Regional lymph node examination

Red Flags

Features raising concern for RMS include:

• Rapidly increasing unilateral proptosis
• Orbital mass in a child
• Progressive eyelid swelling without infectious explanation
• Globe displacement
• Poor response to antibiotics
• Persistent or enlarging “inflammatory” orbital lesion

Imaging

MRI

MRI of the orbits and brain with contrast is generally the preferred imaging study.

MRI provides excellent evaluation of:

• Tumor extent
• Orbital apex
• Optic nerve
• Extraocular muscles
• Intracranial extension
• Adjacent sinus involvement

MRI Appearance

Orbital RMS typically appears as:

• Soft-tissue mass
• T1 iso- to hypointense
• T2 hyperintense
• Contrast enhancing

It may be:

• Well circumscribed
• Infiltrative
• Heterogeneous

Imaging features are not pathognomonic.

CT

CT is particularly useful for evaluating:

• Bone destruction
• Calcification
• Paranasal sinus involvement

Bone erosion is less common in early orbital RMS than in some other aggressive orbital malignancies.

Typical Location

Orbital RMS often occurs in the:

• Superior orbit
• Superonasal orbit

but it can arise anywhere.

It is commonly:

• Extraconal

although intraconal or diffuse disease can occur.

Systemic Staging

Once RMS is diagnosed, systemic staging is required.

Evaluation may include:

• Chest CT
• Regional lymph node assessment
• MRI of primary site
• FDG PET/CT in many modern protocols
• Bone marrow evaluation in selected higher-risk patients
• Bone imaging depending on risk group and protocol

Staging should follow a pediatric oncology protocol.

Common Metastatic Sites

Potential metastatic sites include:

• Lung
• Bone
• Bone marrow
• Regional lymph nodes

Orbital RMS has a relatively low frequency of nodal spread compared with some head and neck RMS sites.

Biopsy

Definitive diagnosis requires:

Tissue biopsy

The surgical goal is to obtain adequate diagnostic tissue while preserving:

• Vision
• Globe
• Extraocular muscles
• Orbital structures

Surgical Approach

Modern treatment does not generally require aggressive complete orbital excision.

Depending on tumor size and accessibility:

• Incisional biopsy
• Limited excisional biopsy

may be performed.

Wide resection that produces major functional or cosmetic morbidity should generally be avoided because RMS is highly responsive to:

• Chemotherapy
• Radiotherapy

Pathologic Evaluation

Specimens should undergo:

• Histopathology
• Immunohistochemistry
• Molecular testing

including assessment for:

FOXO1 fusion status

when appropriate.

Differential Diagnosis

Important pediatric orbital differentials include:

• Orbital cellulitis
• Idiopathic orbital inflammatory disease
• Lymphatic malformation
• Venous malformation
• Dermoid cyst
• Neuroblastoma metastasis
• Leukemia/chloroma
• Langerhans cell histiocytosis
• Ewing sarcoma
• Optic pathway glioma

Orbital Cellulitis vs RMS

Orbital cellulitis usually has:

• Fever
• Pain
• Sinusitis
• Leukocytosis
• Rapid inflammatory onset

RMS may mimic cellulitis but often shows:

• Persistent mass
• Progressive proptosis
• Limited systemic inflammatory symptoms
• Poor response to antimicrobial treatment

Neuroblastoma Metastasis

Orbital neuroblastoma metastasis often presents with:

• Bilateral orbital disease
• Periorbital ecchymosis
• Proptosis

whereas orbital RMS is usually:

• Primary
• Unilateral

Treatment Principles

Modern therapy is multidisciplinary and generally combines:

• Chemotherapy
• Radiotherapy when indicated
• Limited surgery for diagnosis/local control

Management should involve a pediatric sarcoma oncology team.

Chemotherapy

Systemic chemotherapy is essential because RMS is treated as a systemic-risk malignancy even when apparently localized.

A common backbone includes:

• Vincristine
• Actinomycin D / dactinomycin
• Cyclophosphamide

often referred to as:

VAC chemotherapy

Alternative Chemotherapy Regimens

Depending on:

• Risk group
• Histology
• FOXO1 fusion status
• Clinical trial protocol

regimens may also include:

• Ifosfamide
• Etoposide
• Irinotecan
• Vinorelbine
• Other agents

Therapy is protocol-driven rather than based solely on orbital findings.

Risk Stratification

Modern treatment incorporates:

• Tumor site
• Tumor size
• Nodal status
• Metastatic status
• Surgical/pathologic group
• Histology
• FOXO1 fusion status

The orbit is considered a:

Favorable primary site

in many pediatric RMS classification systems.

Surgical Grouping

Traditional Intergroup Rhabdomyosarcoma Study grouping includes:

Group I

Complete resection with negative margins

Group II

Microscopic residual disease and/or selected nodal involvement

Group III

Gross residual disease after biopsy or incomplete resection

Group IV

Distant metastatic disease at diagnosis

Most orbital RMS cases historically fall into:

Group III

because biopsy rather than mutilating complete excision is preferred.

Radiotherapy

Radiation is an important component of local control in many patients with:

• Residual tumor
• Higher-risk disease
• Fusion-positive disease
• Inadequate response to chemotherapy

Modern techniques aim to minimize dose to:

• Lens
• Retina
• Optic nerve
• Lacrimal gland
• Pituitary
• Developing facial bones

Modern Radiation Techniques

Depending on availability and protocol, options include:

• Intensity-modulated radiotherapy
• Proton beam therapy
• Other conformal techniques

Proton therapy may reduce dose to surrounding developing tissues in selected children.

Timing of Radiation

Radiotherapy timing and dose are individualized based on:

• Risk category
• Response to chemotherapy
• Residual disease
• Age
• Molecular features

Fixed historical dose schedules should not be applied outside modern pediatric oncology protocols.

Role of Surgery

Surgery is primarily used for:

• Diagnostic biopsy
• Limited safe excision
• Selected residual/recurrent disease

Orbital exenteration is almost never part of routine initial treatment.

Modern combined therapy has largely eliminated the need for disfiguring radical surgery.

Recurrence

Recurrence may be:

• Local
• Regional
• Distant

Late recurrence is uncommon but possible.

Any new orbital symptoms after treatment require prompt evaluation.

Management of Recurrent Disease

Treatment may involve:

• Salvage chemotherapy
• Radiation if not previously maximized
• Surgery in selected cases
• Targeted or investigational therapy

Management should occur at a specialized pediatric sarcoma center.

Referral

Any child with a suspicious rapidly enlarging orbital mass should be referred urgently to:

• Pediatric ophthalmology
• Orbital/ocular oncology
• Pediatric oncology

Additional teams may include:

• Radiation oncology
• Pathology
• Genetics
• Neurosurgery
• ENT/head and neck surgery

Genetic Counseling

Genetic evaluation should be considered when there is:

• Strong family history of cancer
• Very young age
• Multiple tumors
• Features of Li-Fraumeni syndrome
• NF1
• Other cancer-predisposition syndrome

Follow-Up

Follow-up is intensive during and after treatment.

Monitoring includes:

• Clinical orbital examination
• Visual function
• MRI of the primary site
• Surveillance for systemic recurrence
• Treatment-related toxicity

Intervals are determined by oncology protocol.

Ophthalmic Monitoring

Monitor for:

• Visual acuity
• Pupillary abnormalities
• Ocular alignment
• Motility
• Exposure keratopathy
• Cataract
• Dry eye
• Radiation retinopathy
• Radiation optic neuropathy

Long-Term Survivorship

Because cure rates are high, long-term treatment effects are increasingly important.

Potential late complications include:

• Cataract
• Dry eye
• Keratoconjunctivitis
• Orbital hypoplasia
• Facial asymmetry
• Strabismus
• Retinal vascular injury
• Optic neuropathy
• Endocrine dysfunction
• Secondary malignancy

Radiation-Related Ocular Complications

Possible complications include:

• Cataract
• Dry eye
• Lacrimal gland dysfunction
• Radiation keratopathy
• Radiation retinopathy
• Optic neuropathy
• Orbital bone growth disturbance

Risk depends on:

• Dose
• Radiation field
• Patient age
• Technique

Chemotherapy Complications

Possible adverse effects include:

• Myelosuppression
• Infection
• Neuropathy
• Hemorrhagic cystitis
• Gonadal toxicity
• Secondary malignancy

depending on agents used.

Prognosis

The prognosis for localized orbital RMS is generally:

Excellent

with modern multimodal therapy.

Long-term survival is often:

>90%

for localized favorable-site orbital disease.

Favorable Prognostic Factors

Include:

• Localized orbital primary
• Embryonal/fusion-negative biology
• Younger age
• No metastatic disease
• Good response to chemotherapy
• Effective local control

Poor Prognostic Factors

Include:

• Distant metastasis
• FOXO1 fusion-positive tumor
• Incomplete local control
• Recurrent disease
• Unfavorable molecular biology

Visual Prognosis

Vision may be preserved if:

• Disease is diagnosed early
• Optic nerve is not severely compressed
• Treatment-related ocular toxicity is minimized

Visual morbidity may result from:

• Tumor itself
• Radiation
• Surgery
• Chemotherapy
• Amblyopia

Complications

Disease-related complications include:

• Progressive proptosis
• Exposure keratopathy
• Optic nerve compression
• Visual loss
• Intracranial extension
• Metastasis

Treatment-related complications include:

• Cataract
• Dry eye
• Radiation retinopathy
• Optic neuropathy
• Orbital growth disturbance
• Secondary malignancy

Ophthalmology Pearls

• Orbital rhabdomyosarcoma is the most common primary malignant orbital tumor of childhood.
• The classic presentation is rapidly progressive unilateral proptosis over days to weeks.
• It may mimic orbital cellulitis or idiopathic orbital inflammation.
• Embryonal RMS is the most common orbital subtype.
• FOXO1 fusion status is now an important prognostic and treatment-stratification marker, especially in alveolar-type disease.
• MRI of the orbits and brain with contrast is the preferred imaging study; CT is useful for bone assessment.
• Definitive diagnosis requires biopsy, but aggressive complete orbital excision is usually unnecessary.
• Modern management relies on systemic chemotherapy plus risk-adapted radiotherapy.
• The standard chemotherapy backbone commonly includes vincristine, dactinomycin, and cyclophosphamide (VAC).
• The orbit is considered a favorable RMS primary site, and localized disease now has an excellent survival rate, often above 90%.
• Orbital exenteration is rarely required in modern initial management.
• Long-term survivors require surveillance for cataract, dry eye, orbital hypoplasia, radiation retinopathy, optic neuropathy, endocrine abnormalities, and secondary malignancy.